The University of Chicago Header Logo

Connection

Olatoyosi Odenike to Receptors, Vascular Endothelial Growth Factor

Back to Details
This is a "connection" page, showing publications Olatoyosi Odenike has written about Receptors, Vascular Endothelial Growth Factor.
Olatoyosi Odenike
Connection Strength
0.028
Receptors, Vascular Endothelial Growth Factor
  1. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct; 31(5):1311-20.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.